key: cord-0917331-fgarwqfy
authors: Gustine, Joshua N.; Jones, Dennis
title: Immunopathology of Hyperinflammation in COVID-19
date: 2020-09-11
journal: Am J Pathol
DOI: 10.1016/j.ajpath.2020.08.009
sha: f6ea874db3f969921639597aea7719441b4a4e71
doc_id: 917331
cord_uid: fgarwqfy

The rapid spread of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in an unprecedented public health crisis worldwide. Recent studies indicate that a hyperinflammatory syndrome induced by SARS-CoV-2 contributes to disease severity and mortality in COVID-19. In this Review, an overview of the pathophysiology underlying the hyperinflammatory syndrome in severe COVID-19 is provided. The current evidence suggests the hyperinflammatory syndrome results from a dysregulated host innate immune response. The gross and microscopic pathological findings as well as the alterations in the cytokine milieu, macrophages/monocytes, natural killer cells, T cells, and neutrophils in severe COVID-19 are summarized. Data also highlighted include the potential therapeutic approaches undergoing investigation to modulate the immune response and abrogate lung injury in severe COVID-19.

In December 2019, severe acute respiratory syndrome coronavirus (SARS-CoV-2) was identified in Wuhan, China as the cause of coronavirus disease 2019 . 1 SARS-CoV-2 represents a novel strain in the coronavirus family, a group of enveloped, positive-sense, singled-stranded RNA viruses. Additional members of this family include the highly pathogenic strains severe acute respiratory syndrome coronavirus (SARS-CoV-1) and Middle East respiratory syndrome coronavirus (MERS-CoV). SARS-CoV-2 shares significant phylogenetic homology with two bat-derived SARS-like coronaviruses, and primarily uses the angiotensin-converting enzyme 2 (ACE2) receptor in humans for cell entry. 2 Following a likely zoonotic spillover event, efficient human-tohuman transmission of SARS-CoV-2 was confirmed and resulted in the rapid global spread of COVID-19. 3 The World Health Organization (WHO) officially declared COVID-19 a pandemic in March 2020.

Clinically, the disease presentation of COVID-19 is markedly heterogeneous.

Cases can range from being asymptomatic or a mild upper respiratory illness to severe viral pneumonia that requires hospitalization and progresses to cytokine storm, acute respiratory distress syndrome (ARDS), and death. [4] [5] [6] Nearly all patients with severe COVID-19 present with bilateral lung involvement. 7 The acute onset of impaired oxygenation with non-cardiogenic pulmonary infiltrates characterizes ARDS, which can develop in 15-40% of patients with COVID-19 associated pneumonia. 4, 6, 8, 9 Approximately 80% of patients with severe disease need supplemental oxygenation, of whom 30-40% require mechanical ventilation. 4, 6, 8, 9 The estimated mortality rate for patients requiring mechanical ventilation approximates 70-90%, and pulmonary failure represents the primary cause of mortality due to COVID-19. 6, 8, 9 Akin to SARS-CoV-1 and MERS-CoV, increasing evidence indicates a hyperinflammatory response to SARS-CoV-2 contributes to disease severity and J o u r n a l P r e -p r o o f death in COVID-19. 10 Patients with severe COVID-19 have elevated clinical inflammatory markers and increased serum cytokine and chemokine levels. 4 These markers of inflammation are prognostic for requiring mechanical ventilation, developing ARDS, and death in COVID- 19. 4, 8, 11-13 Post-mortem analysis has also identified a mononuclear inflammatory infiltrate with lymphocytes and macrophages in the lungs, as well as evidence of hemophagocytosis in the bone marrow and reticuloendothelial organs. [14] [15] [16] [17] Collectively, this hyperinflammatory response shares many biological and clinical characteristics with the macrophage activation syndrome (MAS) seen in viralinduced hemophagocytic lymphohistiocytosis (HLH), 18 suggesting a significant role of the host innate immune system in the immunopathology of COVID-19.

Indeed, several immunomodulatory agents are undergoing investigation to attenuate the immune response to SARS-CoV-2 and abrogate lung injury. In this Review, the inflammatory response in patients with COVID-19 is discussed; in particular, the data that suggest a dysregulated innate immune response drives the hyperinflammatory syndrome in severe COVID-19 are highlighted.

The pathological examination of decedents from COVID-19 has provided important insights into disease pathogenesis. The predominant pattern of lung injury associated with COVID-19 is diffuse alveolar damage accompanied by platelet-fibrin microthrombi in pulmonary vessels. On post-mortem analysis, the gross examination revealed heavy, congested, and diffusely edematous lung parenchyma, consistent with a clinical diagnosis of ARDS. 15 The microscopic findings identified diffuse alveolar hemorrhage in different phases. 14, 15, 17 Most cases were in the early or intermediate proliferative phase with edema, while features consistent with the fibrotic phase were rare. 14, 15, 17 Histological features accompanying the intra-alveolar and interstitial exudate included capillary congestion, dilated alveolar ducts and collapsed alveoli, hyaline membrane formation, and desquamation of pneumocytes. 16, 17 Desquamated pneumocytes J o u r n a l P r e -p r o o f had an apparent viral cytopathic effect and were present in alveolar spaces. 14, 17 Electron microscopy identified viral particles within type 1 and type 2 pneumocytes, 15, 16 and immunofluorescence localized SARS-CoV-2 antigen to the ACE2-positive bronchiolar epithelium. 17 In the majority of cases, microthrombi were present in the small-and mediumsized pulmonary arterial vessels. [15] [16] [17] 19 Increased levels of CD61+ megakaryocytes were also found in alveolar capillaries accompanying the microthrombi. 15, 16 Microthrombi have been identified in nearly all major organs, including the lung, heart, brain, and liver; the location of microthrombi appears to correlate with endothelial ACE2 expression. [15] [16] [17] These microthrombi likely contribute to organ dysfunction and mortality with COVID-19. 15 19 Alveolar capillary microthrombi were nine times as prevalent in lungs from COVID-19 patients compared to influenza A. 19 In addition, COVID-19 patients had increased numbers of ACE2+ endothelial cells and significant histological changes to endothelial cell morphology observed, including disruption of intercellular junctions, cell swelling, and loss of contact with basement membrane. 19 Consistent with a previous study evaluating endothelial cells from glomerular capillary loops, 20 electron microscopy identified SARS-CoV-2 viral particles within alveolar endothelial cells. 19 In vitro studies have also shown SARS-CoV-2 can directly infect an engineered human blood vessel organoid via the ACE2 receptor. 21 These findings suggest direct viral invasion by SARS-CoV-2 may trigger an endothelitis and contribute to endothelial injury in COVID-19. Further work is needed to confirm these data as well as elucidate the mechanism underlying the prothrombotic state in COVID-19.

All COVID-19 patients had a mononuclear inflammatory infiltrate in the lung parenchyma composed primarily of lymphocytes and macrophages. [14] [15] [16] [17] 19 The lymphocytic infiltrate included both CD4+ and CD8+ T cells in the bronchiolar and J o u r n a l P r e -p r o o f alveolar interstitium with a CD4+ T cell predominance. 15, 16, 19 CD4+ T cells appeared to aggregate around small vessels that often contained microthrombi. 15, 16 Large numbers of CD68+ macrophages and multinucleated cells were also identified and localized to the alveolar lumen. [15] [16] [17] The presence of macrophages appeared to correlate with disease advancement. 15 These patient findings have been recapitulated in phenotypic studies using transgenic mice bearing human ACE2 infected with SARS-CoV-2, which showed the characteristic interstitial pneumonia with infiltration of lymphocytes and macrophages in the alveolar interstitium, as well as macrophages in the alveolar lumen. 22 A recent study identified the presence of hemophagocytosis in the bone marrow and reticuloendothelial organs of patients with COVID-19. Bryce et al. reported a comprehensive autopsy series of 67 patients who succumbed to In this study, hemophagocytic macrophages were identified in the lymph nodes (9/11), spleen (9/22), bone marrow (4/6), heart, and liver. Abnormally high mean peak levels of C-reactive protein, ferritin, IL-6, IL-8, and TNF-α accompanied the histopathological findings in these patients. The presence of hemophagocytosis with concomitant elevations in inflammatory cytokines suggests that alveolar macrophage activation can induce an HLH phenotype in patients with severe COVID-19. Severe cases of SARS-CoV-1 shared similar pathological findings. 23

Early studies reporting outcomes to COVID-19 identified that elevated clinical inflammatory markers were prognostic for disease severity and mortality. Two multicenter, retrospective studies of hospitalized patients in China evaluated predictors of mortality to COVID-19. 8, 11 Non-survivors had elevated C-reactive protein, lactate dehydrogenase, serum ferritin, and serum IL-6 levels compared to survivors at the time of hospital admission. 8, 11 In addition, non-survivors had elevated inflammatory markers throughout the entire clinical course, and the J o u r n a l P r e -p r o o f clinical deterioration that preceded death tracked with increasing levels of inflammation. 8 The risk of developing ARDS was also higher in patients with elevated inflammatory markers. 12 Consistent with these initial clinical findings, plasma sampling from patients with severe COVID-19 revealed a pro-inflammatory cytokine profile. The initial report patients with moderate and severe disease had abnormally elevated levels of IL-1β, IL-2R, IL-6, IL-8, IL-10, and TNF-α. 24 In a large retrospective study of 1,484 patients at Mount Sinai, plasma levels of IL-6, IL-8, and TNF-α were higher in patients with severe COVID-19. 13 Moreover, IL-6 and TNF-α levels at the time of hospitalization were independently associated with disease severity and mortality in the multivariate analysis. 13 Elevated plasma levels of IL-6, IL-8, and TNF-α also peaked before death in an autopsy series of COVID-19 patients, and correlated with pathological evidence of hemophagocytosis. 17 macrophage-polarized response. 10, 33 Consequently, a pro-inflammatory feedback loop is established, triggering a cytokine storm that circulates and causes local tissue damage as well as systemic effects, such as septic shock, multi-organ failure, and hemophagocytosis in reticuloendothelial organs. 4, 17, 34 Notably, the tropism of SARS-CoV-2 for ACE2+ type 2 pneumocytes may contribute to the development of a cytokine storm. Viral binding by SARS-CoV-2 to the ACE2 receptor is primarily restricted to type 2 pneumocytes on the lung epithelium. 35 Although typically associated with surfactant production and alveolar repair, type 2 pneumocytes have a specialized role in the innate immune response. Type 2 pneumocytes express Toll-like receptors (TLRs) that activate inflammatory NF-κB signaling in response to binding of viral RNA. [36] [37] [38] Activation of NF-κB triggers the production of cytokines that can induce an inflammatory program in resident macrophages and recruit activated monocytes and T cells to the lung. Accordingly, increased IL-6 levels in hyperplastic type 2 pneumocytes infected with SARS-CoV-2 have been measured. 26 ACE2+-infected pneumocytes also expressed high levels of pro-inflammatory cytokines (i.e., MCP-1/CCL2, TNF-α, IL-1β, and IL-6) in an autopsy series of patients with SARS-CoV-1; J o u r n a l P r e -p r o o f cytokine expression was unchanged in uninfected cells. 39 Direct invasion and stimulation of TLR-containing ACE2+ type 2 pneumocytes may therefore exacerbate cytokine production in COVID-19.

Dysregulated interferon signaling also likely impacts the immunopathology of severe COVID-19. Initial studies suggest SARS-CoV-2 can suppress interferon signaling and impair viral clearance from infected cells. SARS-CoV-2 is sensitive to pretreatment with type I and III interferons in vitro. 40 However, a study using infected cell lines, primary bronchial cells, and a ferret model with SARS-CoV-2 infection demonstrated a decreased type I and III interferon signature. 40 Patients with severe COVID-19 also appear to have impaired type I interferon signatures compared to mild or moderate cases. 41 Whole-blood transcriptome analysis revealed that expression of type I interferon was inversely correlated with the viral load and NF-κB-driven inflammatory response (i.e., IL-6 and TNF-α levels)

in COVID-19 patients. 41 Moreover, a multicenter observational study reported administration of interferon-α2b early in the disease course of COVID-19 improves in-hospital mortality of infected patients. 42 These findings suggest a weak interferon response during the early infection with SARS-CoV-2 may be permissive for developing severe COVID-19.

Additional work is needed to ascertain the mechanism SARS-CoV-2 employs to impair interferon signaling. However, functional studies in other pathogenic coronaviruses, such as SARS-CoV-1 and MERS-CoV, elucidated the viral proteins that antagonize interferon signaling and release. Example virulence mechanisms include inhibition of TANK-binding kinase 1 (TBK1)-dependent phosphorylation, interferon regulatory factor 3 (IRF3) activation, and interferon production. [43] [44] [45] An animal model of SARS-CoV-1 also showed that delayed type I interferon signaling and rapid viral replication induced a hyperinflammatory state with lung pathology. 46 These mice had an excessive accumulation of activated macrophages in the lung as well as elevated cytokine levels and an inadequate virus-specific T cell response. 46 As such, impaired viral clearance of SARS-CoV-J o u r n a l P r e -p r o o f stimulation and pyroptosis of infected type 2 pneumocytes, thereby promoting the hyperinflammatory state observed in severe COVID-19.

A pro-inflammatory macrophage microenvironment defines the landscape of bronchoalveolar immune cells in patients with severe COVID-19. In line with initial pathological findings, single-cell RNA sequencing (scRNA-seq) of bronchoalveolar fluid (BALF) collected from COVID-19 patients identified an abundance of macrophages in severe disease. 32, 47 Further analysis revealed the macrophages are primarily inflammatory monocyte-derived macrophages with a relative paucity of resident alveolar macrophages. 32 The macrophages in severe disease highly express FCN1 (Ficolin-1) and SPP1, while those with moderate disease preferentially express FABP4. 32 attract CD8+ T cells that may be specific for SARS-CoV-2. 32 In both severe and moderate cases, expression of the CXCR3-ligands CXCL9, CXCL10, and CXCL11 was higher compared to healthy controls. 32 These transcriptional changes in lung macrophages also correlated with BALF cytokine levels. Patients with severe disease had significantly higher levels of pro-inflammatory cytokines in BALF, especially IL-1β, IL-6, IL-8, TNF-α, and IFN-γ. 32, 50 Collectively, these data suggest lung macrophages recruit inflammatory monocytes and produce cytokines that contribute to hyperinflammation in severe COVID-19.

A significant expansion of inflammatory monocytes is also present in the peripheral blood of COVID-19 patients. Flow cytometric analysis identified increased populations of CD14 + CD16 + , GM-CSF + CD14 + , and IL-6 + CD14 + subsets of inflammatory monocytes. 51, 52 The percentage of CD14 + CD16 + monocytes producing IL-6 correlated with disease severity. 51 Conversely, a study using scRNA-seq of BALF collected a median 12 days after symptom onset reported increased NK cells in COVID-19 patients. 32 The discrepant findings between studies could be attributed to the timing differences in BALF sample collection, and suggest NK cells may be recruited to the lung later in the disease course of COVID-19. 65 Trafficking of NK cells is further supported by the expansion of lung macrophages that produce CXCR3 ligands (CXCL9, CXCL10, CXCL11) in COVID-19. 32 CXCR3 has been previously shown to promote NK cell recruitment to the lung in influenza infection. 66 It is possible that cell death may also contribute to peripheral NK cell depletion since transcription of P53 and apoptosis pathways in peripheral lymphocytes are J o u r n a l P r e -p r o o f upregulated in COVID-19 patients. 50 While the absence of ACE2 receptors makes SARS-CoV-2 infection of NK cells unlikely, 35 circulating cytokines could play a role since peripheral NK cell counts inversely correlate to serum IL-6 levels. 63 Additional studies are nonetheless needed to delineate the processes involved in peripheral NK cell depletion, including whether the cytokine storm leads to NK cell apoptosis.

The cytokine milieu also may confer the exhausted phenotype of peripheral NK cells in COVID-19. In particular, studies have shown IL-6 and TNF-α can impair the cytolytic function of NK cells. In healthy donor NK cells, in vitro stimulation of the soluble IL-6 receptor (IL-6R) by IL-6 reduces the production of perforin and granzyme, which can be reversed by IL-6R antagonism with tocilizumab. 67 These findings suggest IL-6 might hasten the downregulation of granzyme expression on NK cells reported in COVID-19. 62 However, additional experiments are needed to confirm these findings in NK cells derived from COVID-19 patients.

licensing is also likely occurring; CD16 expression was inversely correlated to serum IL-6 levels in COVID-19 patients. 63 In addition, ligand-receptor analysis with scRNA-seq of peripheral blood revealed interactions between inflammatory monocytes and NK cells in severe COVID-19. 55 The data show TNF-α may interact with its receptor, TNFR1, on NK cells. 55 The impact of this cytokinereceptor interaction in COVID-19 needs investigation, but in the tumor microenvironment it results in the downregulation of the major NK cell-activating receptor NKp46, especially on CD56 high NK cells. 68 Taken together, the above findings suggest crosstalk with monocytes and macrophages via cytokines might mediate NK cell dysfunction and impair clearance of SARS-CoV-2. 69 Persistent infection with SARS-CoV-2 could subsequently exacerbate the pro-inflammatory feedback loop underlying the cytokine storm in severe COVID-19.

The occurrence of a profound lymphopenia in patients with COVID-19 is well established. The absolute lymphocyte count is prognostic for disease severity and mortality, and significant reductions in peripheral CD4+ and CD8+ T cells manifest in both moderate and severe cases of COVID-19. 4, 8, 9, 11, 24, 62, 64 Serum cytokine levels are inversely correlated with CD4+ and CD8+ T cell counts, and improved cytokine levels are associated with the reversal of lymphopenia in the convalescent period of recovered patients. 4, 8, 13, 62, 64 In decedents who had lymphopenia, autopsy evaluation revealed the extensive cell death of lymphocytes in the lymph nodes and spleen; SARS-CoV-2 infected spleens and lymph nodes also overexpressed the apoptotic protein Fas. 17, 70 Likewise, transcriptomic analysis identified upregulation of apoptotic pathways in lymphocytes from the peripheral blood of COVID-19 patients. 50 Hemophagocytic macrophages present in the spleen and lymph nodes accompanied the lymphocyte depletion, 17 suggesting a role for aberrantly activated macrophages in lymphopenia. These macrophages also express high levels of IL-6, which may promote lymphocyte necrosis and apoptosis. 70 Indeed, antagonism of the IL-6R with tocilizumab results in increased peripheral lymphocyte counts in COVID- 19 . 64 Trafficking of peripheral T cells to the lung also likely contributes to the lymphopenia. As previously discussed, autopsy studies reported a pulmonary lymphocytic interstitial infiltrate with CD4+ and CD8+ T cells, [14] [15] [16] [17] 

Increasing evidence indicates the dysregulated myeloid response to SARS-CoV-2 extends to neutrophils in severe COVID-19. An elevated absolute neutrophil count and neutrophil-to-lymphocyte ratio are prognostic for ARDS and death in 8, [11] [12] [13] 24 Patients with severe COVID-19 also have increased levels 72 The milieu of patients with COVID-19 appears to promote formation of NETs, as exposure of healthy neutrophils to serum collected from hospitalized COVID-19 patients triggers significant NETosis. 71, 72 Further work is needed to delineate the mechanism of NET formation in COVID-19, but activation of neutrophils by viral nucleic acids and cytokines might have a role. [71] [72] [73] J o u r n a l P r e -p r o o f Importantly, NETs may contribute to the development of lung injury and microthrombi in COVID-19. Dysregulated NETosis has been previously shown to cause excessive lung injury and immunothrombosis in response to other respiratory viruses and bacteria. 74 A recent study evaluating autopsy lung specimens for NETs reported pathological evidence suggestive of dysregulated NETosis in COVID-19. 71 Immunofluorescence revealed a neutrophilic infiltrate in the lungs with numerous Cit-H3+ and MPO+ neutrophils as well as lattices of extracellular DNA with Cit-H3 and MPO. 71 In addition, the study reported the colocalization of Cit-H3+ neutrophils likely undergoing NETosis with PF4+ platelets in pulmonary blood vessels, 71 Nearly all patients with MIS-C present with fever. [75] [76] [77] [78] Multiple organ systems are involved in most patients; gastrointestinal (92%), cardiovascular (80%), hematologic (76%), mucocutaneous (74%), and respiratory systems (70%) are the most commonly involved. 75 The majority of patients require admission to the ICU for treatment. [75] [76] [77] [78] Invasive and non-invasive mechanical ventilation for respiratory insufficiency or failure are needed in 20% and 17% of patients, respectively. 75 The estimated mortality rate from MIS-C is approximately 0-2%. [75] [76] [77] [78] J o u r n a l P r e -p r o o f An important finding was the high incidence of cardiovascular involvement in MIS-C. The majority of patients had elevated brain natriuretic peptide and troponin levels. [75] [76] [77] [78] Nearly half of the patients had hypotension or cardiogenic shock, which prompted vasopressor support in one-quarter of patients. [75] [76] [77] [78] On echocardiogram, ventricular dysfunction (ejection fraction <55%) was identified in approximately half of patients. [75] [76] [77] [78] Approximately 8-21% of patients also had coronary artery aneurysms identified in either the left descending artery or right coronary artery, consistent with a Kawasaki-like vasculitis presentation of MIS-C. [75] [76] [77] [78] The immunologic findings in MIS-C are similar to those described in adults with severe COVID-19. Nearly all MIS-C patients had multiple laboratory markers of inflammation, including an elevated erythrocyte sedimentation rate, C-reactive protein, and ferritin. [75] [76] [77] [78] Serum cytokine analysis showed elevated IL-6, IL-10, and soluble IL-2R levels. 77 Patients with MIS-C also displayed lymphopenia including reduced levels of CD4+ and CD8+ T cells as well as NK cells. 77 Notably, the majority of MIS-C patients had positive SARS-CoV-2 serologies, 77 and the median time interval elapsed between COVID-19 symptom onset and MIS-C symptom onset was 25 days. 75 These findings support the current hypothesis that MIS-C represents an immune-mediated post-infectious process to SARS-CoV-2. 75, 77 Although MIS-C is a rare complication of COVID-19, additional studies are needed to understand the pathophysiology, therapeutic management, and long-term sequelae of this complication.

The evidence of a dysregulated host immune response has prompted the investigation of immunomodulatory therapies to abrogate lung injury in COVID-19. There are more than 2,500 studies currently registered on ClinicalTrials.gov for COVID-19, including many evaluating immunomodulators alone or in combination with other agents. These clinical trials will need to determine the Table 1 .

Corticosteroids have widespread inhibitory effects on the immune system and are efficacious in managing acute inflammatory processes. 79 Dexamethasone was also more effective in patients randomized to treatment >7 versus ≤7 days after the onset of COVID-19 symptoms (p<0.001). 79 Dexamethasone is the first therapy shown to improve survival in patients with COVID-19.

The identification of respiratory support as a predictor of dexamethasone efficacy has provided insights into the disease stages of COVID-19. Previous studies have shown that inflammatory markers track with disease progression and clinical deterioration in COVID- 19. 4, 8, 11-13, 24 Consistent with these findings, the benefit of immune suppression with dexamethasone was only apparent in patients requiring respiratory support, as well as those randomized to treatment >7 days after symptom onset. 79 These data suggest the patients were in a later disease stage dominated by immunopathology. Conversely, patients not requiring respiratory support, who were likely without significant inflammation, J o u r n a l P r e -p r o o f had no benefit and a trend towards potential harm with dexamethasone. 79 antagonist anakinra to block the activity of IL-1β and inflammasome signaling in patients with severe COVID-19. 90, 91 Anakinra is effective in patients with secondary HLH, including when triggered by viral infections, as well as sepsis in those with hyperinflammation. 92, 93 In severe COVID-19, anakinra was associated with rapid reductions in C-reactive protein and progressive improvements in respiratory function (i.e., PaO 2 :FiO 2 ratio). 90 Similar to IL-6R antagonism with tocilizumab, anakinra also had an increased risk of infections. 90, 91 Randomized, controlled studies investigating tocilizumab, anakinra, and additional selective cytokine inhibitors are ongoing to clarify the clinical benefit in severe COVID-19.

The dependence on BTK to transmit pro-inflammatory TLR/IL-1R signaling in monocytes has prompted the consideration of BTK inhibitors to abrogate the cytokine storm in COVID-19. BTK inhibitors are approved and widely used for patients with B cell malignancies and chronic graft-versus-host disease (cGVHD).

In these patients, the BTK inhibitor ibrutinib markedly reduced levels of inflammatory cytokines and chemokines (i.e., IL-6, TNF-α, GM-CSF, IP-10/CXCL10, MCP-1/CCL2, MIP-1α/CCL3, MIP-1β/CCL4) that overlap with those elevated in the plasma and BALF of severe COVID-19 patients. [94] [95] [96] Ibrutinib also blocked pulmonary cytokine production and lethal lung injury in a mouse influenza model. 97 Treon et al. initially reported a possible clinical benefit of ibrutinib in a case series of Waldenström macroglobulinemia patients infected with COVID-19. 98 Results from a pilot study (n=19) of another BTK inhibitor, acalabrutinib, were recently reported for severe patients hospitalized with COVID-19. 52 Following initiation of acalabrutinib, most patients had normalization of C-reactive protein, IL-6, and lymphocyte levels. 52 This decrease in J o u r n a l P r e -p r o o f inflammation correlated with improved respiratory function and oxygenation; 73% of patients requiring supplemental oxygenation were discharged on room air, and 50% of patients on mechanical ventilation were extubated. 52 Randomized, controlled studies evaluating the BTK inhibitors ibrutinib, acalabrutinib, and zanubrutinib in severe COVID-19 are ongoing and results are awaited.

Hydroxychloroquine has been proposed as a treatment for COVID-19 based on in vitro activity against SARS-CoV-2. Although the mechanism of antiviral action is poorly defined, hydroxychloroquine increases the pH of endosomes used by the virus for cell entry and interferes with viral binding to cellular receptors. 99 Antiinflammatory actions of hydroxychloroquine have also been demonstrated, including inhibition of TLR signaling and cytokine production. 100 105 The study found no difference in 28-day mortality between patients randomized to hydroxychloroquine versus usual care (26.8% versus 25.0%; p=0.18). 105 Moreover, hydroxychloroquine was associated with a longer time to discharge (median 16 versus 13 days) and an increased risk of mechanical ventilation or death among patients not on invasive mechanical ventilation at baseline (HR 1.12, 95% CI 1.01-1.25) compared to usual care. 105 The WHO also recently discontinued the SOLIDARITY study, a randomized, controlled trial evaluating hydroxychloroquine versus supportive care in hospitalized COVID-19 patients, due to a lack of mortality benefit (https://www.who.int/news-room/detail/04-07-2020-who-discontinueshydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19; Accessed on July 18, 2020). Randomized, controlled studies evaluating hydroxychloroquine in patients with mild or moderate COVID-19 disease as well as post-exposure prophylaxis similarly showed no clinical benefit. [106] [107] [108] J o u r n a l P r e -p r o o f

The rapid spread of SARS-CoV-2 has resulted in an unprecedented public health crisis worldwide. Although COVID-19 is typically asymptomatic or mild in the majority of cases, it can manifest as severe viral pneumonia that leads to mechanical ventilation and death. The natural history of COVID-19 includes an initial stage of viral replication that can be followed by a second stage of immunopathology driven by a hyperinflammatory response to SARS-CoV-2. This Review presented the current evidence indicating that a dysregulated host innate immune response underlies the hyperinflammatory syndrome in COVID-19; the disease mechanism is summarized in Figure 1 . The syndrome shares overlapping features with a viral-induced HLH, including evidence of macrophage activation with a cytokine storm, NK cell and CD8+ T cell impairment, and hemophagocytic macrophages. Therapies modulating the immune response may be critical to treat and prevent immunopathology in patients who progress to severe disease. Given the rapidly evolving nature of the COVID-19 pandemic, studies that have not yet completed the peer-review process were discussed herein to present the most recent data available, but should be interpreted with caution as the conclusions may change. Future studies need to identify the exact drivers of pathological inflammation and biomarkers that predict which patients will develop a hyperinflammatory response to SARS-CoV-2. The results of these studies will enable identification of the most appropriate immunomodulating agents as well as the optimal timing of such interventions to achieve maximal therapeutic benefit in patients with COVID-19. 

A Novel Coronavirus from Patients with Pneumonia in China

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet

Feng Z: Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet

Clinical Characteristics of Coronavirus Disease 2019 in China

Consortium atNC-R: Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

COVID-19: consider cytokine storm syndromes and immunosuppression

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

An inflammatory cytokine signature helps predict COVID-19 severity and death

Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine 2020

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study

M: Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response

Adult haemophagocytic syndrome

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid

Endothelial cell infection and endotheliitis in COVID-19

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

Malik Peiris JS: Lung pathology of fatal severe acute respiratory syndrome

Clinical and immunological features of severe and moderate coronavirus disease 2019

The trinity of COVID-19: immunity, inflammation and intervention

Massive viral replication and cytopathic effects in early COVID-19 pnuemonia

Histopathologic Changes and SARS-CoV-2 Immunostaining in the Lung of a Patient With COVID-19

Apoptosis, Pyroptosis, and Necrosis: Mechanistic Description of Dead and Dying Eukaryotic Cells

Cell Pyroptosis, a Potential Pathogenic Mechanism of 2019-nCoV Infection

Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19

Early Insights into Immune Responses during COVID-19

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

Hill AM: M-1/M-2 Macrophages and the Th1/Th2 Paradigm

Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues

CCR2 and CXCR3 agonistic chemokines are differently expressed and regulated in human alveolar epithelial cells type II

Innate Immune Responses to Bacterial Ligands in the Peripheral Human Lung -Role of Alveolar Epithelial TLR Expression and Signalling

Alveolar epithelial cells are critical in protection of the respiratory tract by secretion of factors able to modulate the activity of pulmonary macrophages and directly control bacterial growth

Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients

SARS coronavirus papain-like protease inhibits the type I interferon signaling pathway through interaction with the STING-TRAF3-TBK1 complex

Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets

Middle East respiratory syndrome coronavirus M protein suppresses type I interferon expression through the inhibition of TBK1-dependent phosphorylation of IRF3

Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice

Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients

Abnormal pulmonary function in COVID-19 patients at time of hospital discharge

Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study

Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerging Microbes & Infections 2020

Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

Immune cell profiling of COVID-19 patients in the recovery stageby single-cell sequencing

A Dynamic Immune Response Shapes COVID-19 Progression

Single-cell analysis of severe COVID-19 patients reveals a monocyte-driven inflammatory storm attenuated by Tocilizumab

Bruton's tyrosine kinase regulates TLR7/8-induced TNF transcription via nuclear factor-κB recruitment

Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury

BTK operates a phosphotyrosine switch to regulate NLRP3 inflammasome activity

Pathogen Recognition and Innate Immunity

MyD88 is required for protection from lethal infection with a mouseadapted SARS-CoV

A single-cell atlas of the peripheral immune response in patients with severe COVID-19

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?

Natural Killer Cell Recruitment to the Lung During Influenza A Virus Infection Is Dependent on CXCR3, CCR5, and Virus Exposure Dose

Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome

TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer. Oncoimmunology

The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes

Neutrophil Extracellular Traps (NETs) Contribute to

Neutrophil extracellular traps in COVID-19

Targeting potential drivers of COVID-19: Neutrophil extracellular traps

Neutrophil Extracellular Traps in Pulmonary Diseases: Too Much of a Good Thing? Frontiers in Immunology

Multisystem Inflammatory Syndrome in Children in

Son MBF: Distinct clinical and immunological features of SARS-COV-2-induced multisystem inflammatory syndrome in children

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Virological assessment of hospitalized patients with COVID-2019

Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome

Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Effective treatment of severe COVID-19 patients with tocilizumab

Tocilizumab treatment in COVID-19: A single center experience

Tocilizumab for treatment of mechanically ventilated patients with COVID-19

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Interleukin-1 blockade with highdose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

Anakinra for severe forms of COVID-19: a cohort study

Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome

Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial*

Disruption of <em>in vivo</em> Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib -Findings from an Investigator-Initiated Phase II Study

CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib

Ibrutinib for chronic graft-versus-host disease after failure of prior therapy

Inhibiting Bruton's tyrosine kinase rescues mice from lethal influenzainduced acute lung injury

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients

Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal

Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data

Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial

The authors gratefully acknowledge Tyler Kalajian for creating the disease mechanism figure of severe COVID-19.J o u r n a l P r e -p r o o f

*Source: https://wwwcovid19treatmentguidelinesnihgov/immune-based-therapy/immunomodulators/corticosteroids/; Accessed on August 19, 2020. †Source: https://wwwfdagov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergencyuse-authorization-chloroquine-and; Accessed on August 19, 2020.